不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
T 细胞受体库在弥漫大 B 细胞淋巴瘤诊断与复发之间呈现动态变化
英文原题：T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.
查看英文原题
T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
复发/难治性 DLBCL 中 T 细胞多样性降低，这可能对免疫治疗的使用具有意义。
研究思路结论见上方概要
背景
TIL（肿瘤浸润淋巴细胞）T细胞受体（TCR）库在新诊断的弥漫性大B细胞淋巴瘤（DLBCL）中具有预后价值，但在复发时的演变尚未得到评估。
方法
我们检测了9对配对DLBCL样本（诊断时和复发时）中的TCR库。
结果
我们注意到显著差异，诊断时的优势克隆在复发时被最初不存在或次要的新克隆所取代。诊断样本与复发样本之间的线性相关性较低（r值为0.01-0.316），共享克隆平均为8.3%（范围0%-37%）。复发样本中的克隆多样性减少，表明肿瘤内免疫反应日益失效。
展开英文摘要原文
BACKGROUND
Tumour infiltrating lymphocyte (TIL) T-cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B-cell lymphoma (DLBCL), but evolution has not been evaluated at relapse.
METHODS
We examined the TCR repertoire in nine paired DLBCL samples from diagnosis and relapse.
RESULTS
We noted considerable differences, with dominant clones at diagnosis replaced at relapse by new clones that were absent or minor initially. There was low linearity between diagnostic and relapsed samples ( r -values 0.01-0.316), with shared clones averaging 8.3% (range 0%-37%). Clonal diversity was reduced in relapsed samples, suggesting an increasingly defunct intratumoural immune response.
CONCLUSION
T-cell diversity is reduced in relapsed/refractory DLBCL, which may have implications for immunotherapy usage.
论文信息
- 作者
- Wight J、Witkowski T、Keane C、Hawkes EA
- 单位
- Austin Health Heidelberg Australia.Germany
- 期刊
- EJHaem2025 Aug
- 原文标识
- PubMed 40630397 · DOI 10.1002/jha2.70097
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →